Jennifer Smit to Medroxyprogesterone Acetate
This is a "connection" page, showing publications Jennifer Smit has written about Medroxyprogesterone Acetate.
Connection Strength
1,822
-
The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial. PLoS One. 2024; 19(8):e0307736.
Score: 0,227
-
Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial. PLoS One. 2024; 19(5):e0299802.
Score: 0,222
-
Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. Contraception. 2004 Jan; 69(1):3-7.
Score: 0,217
-
Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN. PLoS One. 2023; 18(12):e0295959.
Score: 0,217
-
Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South Africa. Soc Sci Med. 2002 Nov; 55(9):1511-22.
Score: 0,200
-
Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. Sex Transm Infect. 2021 06; 97(4):249-255.
Score: 0,175
-
Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception. S Afr Med J. 2011 Feb; 101(2):131-5.
Score: 0,089
-
Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception. 2010 Jan; 81(1):30-4.
Score: 0,082
-
Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception. Contraception. 2009 Aug; 80(2):128-32.
Score: 0,078
-
Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception. 2009 May; 79(5):345-9.
Score: 0,077
-
Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. Contraception. 2007 Jun; 75(6):438-43.
Score: 0,068
-
Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial. PLoS One. 2024; 19(3):e0295764.
Score: 0,055
-
Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate. Contraception. 2003 Nov; 68(5):339-43.
Score: 0,054
-
Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa. Contraception. 2022 04; 108:37-43.
Score: 0,047
-
Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception. 2005 Mar; 71(3):170-5.
Score: 0,015